Previous close | 1.7900 |
Open | 1.7900 |
Bid | 1.7600 x 100 |
Ask | 1.8400 x 100 |
Day's range | 1.7620 - 1.8500 |
52-week range | 0.7200 - 4.1900 |
Volume | |
Avg. volume | 218,411 |
Market cap | 87.289M |
Beta (5Y monthly) | 1.04 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5600 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.63 |
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript March 19, 2024 Corvus Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.14 EPS, expectations were $-0.14. CRVS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon everyone. […]
Q4 2023 Corvus Pharmaceuticals Inc Earnings Call